Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-08-01
|
Series: | The Innovation |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666675820300412 |
id |
doaj-bdbdb47360f5403bb48d34c168d4940d |
---|---|
record_format |
Article |
spelling |
doaj-bdbdb47360f5403bb48d34c168d4940d2021-02-07T04:25:51ZengElsevierThe Innovation2666-67582020-08-0112100041Current Status and Future Perspective of Immunotherapy in Gastrointestinal CancersZhihao Lu0Zhi Peng1Chang Liu2Zhenghang Wang3Yakun Wang4Xi Jiao5Jian Li6Lin Shen7Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, China; Corresponding authorDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, China; Corresponding authorGastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future.http://www.sciencedirect.com/science/article/pii/S2666675820300412gastrointestinal cancerimmune checkpoint blockadebiomarkersprecision immunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhihao Lu Zhi Peng Chang Liu Zhenghang Wang Yakun Wang Xi Jiao Jian Li Lin Shen |
spellingShingle |
Zhihao Lu Zhi Peng Chang Liu Zhenghang Wang Yakun Wang Xi Jiao Jian Li Lin Shen Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers The Innovation gastrointestinal cancer immune checkpoint blockade biomarkers precision immunotherapy |
author_facet |
Zhihao Lu Zhi Peng Chang Liu Zhenghang Wang Yakun Wang Xi Jiao Jian Li Lin Shen |
author_sort |
Zhihao Lu |
title |
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers |
title_short |
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers |
title_full |
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers |
title_fullStr |
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers |
title_full_unstemmed |
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers |
title_sort |
current status and future perspective of immunotherapy in gastrointestinal cancers |
publisher |
Elsevier |
series |
The Innovation |
issn |
2666-6758 |
publishDate |
2020-08-01 |
description |
Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future. |
topic |
gastrointestinal cancer immune checkpoint blockade biomarkers precision immunotherapy |
url |
http://www.sciencedirect.com/science/article/pii/S2666675820300412 |
work_keys_str_mv |
AT zhihaolu currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers AT zhipeng currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers AT changliu currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers AT zhenghangwang currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers AT yakunwang currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers AT xijiao currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers AT jianli currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers AT linshen currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers |
_version_ |
1724281950150066176 |